REG - Arecor Therapeutics - Enhanced IP Coverage: AT278 & Oral Peptide Program

Arecor TherapeuticsAnnouncement

Today 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20251104:nRSD0145Ga&default-theme=true

RNS Number : 0145G  Arecor Therapeutics PLC  04 November 2025

 

Arecor Therapeutics plc

("Arecor" or the "Company")

 

Arecor Enhances IP Coverage for AT278 and Oral Delivery Technology

 

Cambridge, UK, 4 November 2025: Arecor Therapeutics plc (AIM: AREC), the
biopharmaceutical company focused on drug development and delivery in diabetes
and other cardiometabolic diseases, provides an update on the broadening of
its IP position.

AT278 IP

Arecor has strengthened its patent protection for its lead programme, AT278,
the only ultra-concentrated and ultra-rapid acting insulin in development with
the potential to enable longer-wear for existing automated insulin delivery
(AID) systems and their future miniaturisation. A US patent has been granted
to protect key formulations and uses of AT278. In addition, another patent
with respect to AT278 intellectual property has been approved for grant by the
European Patent Office, providing further patent protection in Europe.

Oral peptide delivery IP

Arecor has also filed a patent application with the European Patent office,
claiming novel compositions to improve the oral bioavailability of complex
peptides. Novel peptide therapeutics are proving to be highly effective to
treat chronic conditions such as obesity, diabetes and other cardiometabolic
diseases, and there is growing evidence that oral delivery improves patient
compliance and adherence.

Poor oral bioavailability remains a major barrier to developing convenient
oral peptide therapies. Arecor is addressing this challenge through novel
therapeutic formulations designed to improve the oral bioavailability of
peptides. The new patent application protects the key formulation design space
discovered in initial investigations with additional patent applications
expected to follow as R&D progresses.

Dr Jan Jezek, CSO of Arecor said:

"As an innovative company developing novel therapies and platforms, protecting
our IP is essential to our business. We are continuously updating our IP
protection to secure its value and we are pleased to have received additional
patent protection in Europe and the US for our ultra-concentrated ultra-rapid
acting insulin, AT278. We have also filed our first patent application in the
oral peptide delivery space, which is an important moment for us, with more to
come as our R&D programme progresses."

The new patents add to a robust global intellectual property portfolio of the
Company protecting AT278 and the Arestat® technology, and follow a number of
additional patents already granted in major territories.

-ENDS-

 

For more information, please contact:

 

 Arecor Therapeutics plc                                 +44 (0) 1223 426060

Dr Sarah Howell, Chief Executive Officer

David Ellam, Chief Financial Officer                   info@arecor.com

 Singer Capital Markets Advisory LLP (NOMAD and Broker)  +44 (0) 20 7496 3000
 Phil Davies, Sam Butcher

 Vigo Consulting                                         +44 (0) 20 7390 0230
 Melanie Toyne-Sewell, Rozi Morris

                                                         arecor@vigoconsulting.com

 

Notes to Editors

 

About Arecor

Arecor Therapeutics plc is a clinical stage biopharmaceutical company focused
on drug development and delivery in diabetes and other cardiometabolic
diseases. The Company is applying its proprietary technology platform,
Arestat®, to develop a portfolio of proprietary products, as well as working
with leading pharmaceutical and biotechnology companies to deliver therapeutic
products. Its lead product is AT278, the only ultra-concentrated (500U/mL)
ultra-rapid acting insulin. Arecor is also developing a novel oral delivery
platform for peptides (e.g. GLP-1 receptor agonists) targeting the obesity and
diabetes markets. The Company is listed on AIM (AIM: AREC) and is based in
Cambridge, UK.  For further details please see www.arecor.com
(http://www.arecor.com) .

Arecor® and Arestat® are registered trademarks of Arecor Limited.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCEAFFDELLSFAA



            Copyright 2019 Regulatory News Service, all rights reserved